2-aminotetralin has been researched along with erythrosine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Capone, C; Carminati, P; De Simoni, MG; Fabrizi, C; Fumagalli, L; Ghirardi, O; Marzorati, P; Piovesan, P; Principato, MC | 1 |
1 other study(ies) available for 2-aminotetralin and erythrosine
Article | Year |
---|---|
2-Aminotetraline derivative protects from ischemia/reperfusion brain injury with a broad therapeutic window.
Topics: Amphetamines; Animals; Behavior, Animal; Brain Diseases; Cerebrovascular Circulation; CHO Cells; Cricetinae; Cricetulus; DNA, Complementary; Fluoresceins; Immunohistochemistry; Infarction, Middle Cerebral Artery; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microglia; Nerve Degeneration; Neuroprotective Agents; Organic Chemicals; Receptor, Serotonin, 5-HT2B; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Tetrahydronaphthalenes | 2007 |